is...optimistic for the future of CNS conditions thanks to Anavex Life Sciences.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Stink bid is in for a few thousand more shares at .30
??
No worries.
Thanks for all that you do!
Sticky please? Or can it be added to an updated Due Diligence posting to be placed atop the message board?
Alight. They’re absolute thieves.
Company I used to work for chose poorly for our plan. Dig it: $12.95 per transaction!
Damn the 401k...
Could add 80000 shares if it weren’t for OTC/Pink restrictions.
Ah well.
GLTA. Polymedix/CTIX/IPIX will come to fruition!
Thinking...
Sell a few shares of Novavax to get even more shares of IPIX (the upside is good on both.) ??
Yeah...HIV has been notorious due to its mutation rate
Can’t even imagine how amazing Brilacidin could potentially be for knocking it back. It certainly has the characteristics of a “silver bullet”.
Consider Novavax and Serum Institute’s under-the-radar collaboration for Malaria Vaccine
“Praha Vaccines is a subsidiary of the Cyrus Poonawalla Group, the parent company of Serum Institute of India focused on manufacturing immuno-biologicals.
In March, Serum Institute of India and Novavax signed a commercial license agreement to leverage Novavax’s Matrix-M vaccine adjuvant with the institute’s malaria vaccine candidate.
Novavax president and CEO Stanley Erck said: “This acquisition provides the vital assets required to produce more than one billion doses per year.“
Now, couple that with recent news of:
“Joining the company's leadership team as chief medical officer is Filip Dubovsky, an AstraZeneca veteran. Dubovsky joins Novavax directly from the British drugmaker, where he served as head of clinical engagement and policy, plus as chief medical officer for clinical affairs. Before that role, he oversaw a portfolio of more than two dozen malaria vaccines at the PATH Malaria Vaccine Initiative.”
Yes, Novavax is well situated for NanoFlu, as well as Coronavirus, and the RSV vaccine too.
Everything is lining up for Novavax’s entire pipeline to be brought into play within 2-3 years, if not sooner.
New global vaccination powerhouse.
Gotta’ say it’s heartwarming when the whole Castagna Family purchases shares!
https://ih.advfn.com/stock-market/NASDAQ/mannkind-MNKD/stock-news/82673744/statement-of-changes-in-beneficial-ownership-4
Wish Alfred Mann were still alive for the months ahead.
Brilacidin is THE compound of the future.
We get to witness the successor to old school antibiotics!
Could someone please add petemantx’s post #302295 to the sticky section?
Thanks in advance.
Still in the retail buyer’s dream range!
Once it goes past $5 and institutions start buying, then it’s in Novavax territory.
And not just for COVID-19!
Finally getting the recognition it deserves as a defensin mimetic! SOLID!
Beat me to it!
Funding is now solidified.
Can’t wait for the entire pipeline to be fully developed!
Soon to be the world’s best vaccine company.
But hey...no big deal, right?!
“The proposed research aims to evaluate Brilacidin as a potential pan-coronavirus therapeutic, for treating SARS-CoV-2, SARS-CoV-1 and MERS-CoV, including extending the current in vitro testing of Brilacidin to in vivo testing. Longer-term objectives include potentially performing additional research to develop Brilacidin as a broad-spectrum antiviral, with possible application beyond coronaviruses, e.g., treating other viruses, such as encephalitic alphaviruses and filoviruses.”
One more time for the naysayers...
http://ir.novavax.com/news-releases/news-release-details/novavax-awarded-department-defense-contract-covid-19-vaccine
Concerning manipulation and share price...
When IPIX was CTIX there was an anonymous outfit calling itself “Mako Research” and it would generate BS attacks on companies claiming lawsuits, etc.
https://www.bizjournals.com/boston/news/2017/03/20/an-anonymous-blogger-angers-biotech-investors-but.html
Long story short (no pun intended), the share price took a severe hit despite positive outcomes in trials for Brilacidin.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=116165363
Plus a small retweaking on the RSV and it will be ready too.
(And news will be due from the Malaria and Rabies studies.)
NVX-CoV2373
This is the week of injections.
https://www.9news.com.au/national/coronavirus-nvxcov2373-vaccine-testing-to-start-in-australia-by-nucleus-network/43f9310c-5ed6-4537-8cf7-e37095bfbff2
Thank you Aussie volunteers!
For optimal dosing via inhalation, I’d go with the Technosphere platform c/o MannKind and United Therapeutics
https://seekingalpha.com/article/4295249-mannkinds-technosphere-platform-issues-are-worth-discussing
Nebulizing Brilacidin would probably be pretty effective though, especially since the mist would go directly into the alveoli where the drug is most needed for treatment in the lungs.
“The Polymedix scientists, DeGrado,Klein,Scott and others who developed Brilacidin will have a shot at the Nobel prize.“
Imagine, after all these years, such recognition on a much-belated accomplishment. Heavy stuff.
Thanks GBA.
Doing searches for phosphodiesterase-4 (PDE4) turns up relevant info
https://www.cochrane.org/CD002309/phosphodiesterase-4-inhibitors-people-chronic-obstructive-pulmonary-disease-copd
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6199465/
Really zeroes in on anti inflammatory properties associated with Brilacidin.
That, coupled with existing info regarding ABBSI and Brilacidin’s antimicrobial qualities is a plus.
https://docksci.com/an-independent-evaluation-of-a-novel-peptide-mimetic-brilacidin-pmx30063-for-ocu_5a29cee5d64ab2118322e5e2.html. (old, but good)
Naaaah...
It’s always a pleasure when shorts are forced to contribute to the upward momentum.
Double down on that short position!
Things to consider for Brilacidin...
Likely to become the new standard of care for Oral Mucositis.
Promising results for ABSSSI as well.
Irritable Bowel disease (inflammatory conditions + resistant bacterial infestations) indications are also looking auspicious.
Now it’s being evaluated and advanced along with some other candidates for showing its efficacy in disrupting the wall of the coronavirus. (As if it’s not going to get noticed in the process?! Are you kidding? What big pharma wouldn’t want to add this gem to their collection and reap the rewards?)
Without rehashing all the terminology associated with the aforementioned positives, we’re sitting on a winner. Just a question of when the egg “hatches”.
BETTER SLEEP
Without side effects. Even better. Better functioning at the cellular level!
Defensive-mimetic for the win!
https://en.wikipedia.org/wiki/Defensin" rel="nofollow" target="_blank" >insert-text-here
https://en.wikipedia.org/wiki/Brilacidin" rel="nofollow" target="_blank" >insert-text-here
We’ve got the goods.
Pharmaceutical companies over more than a decade have spent billions of dollars on research to find a treatment for Alzheimer's. Research has largely focused on the beta amyloid protein
Thanks kevli.
Some relevant info (pharmacovigilance)
https://en.wikipedia.org/wiki/Pharmacovigilance" rel="nofollow" target="_blank" >insert-text-here
NVX-CoV2373 (any guesses on future trade name?!)
Novavax is going to crush it.
Not only with NanoFlu, but everything else they have in their pipeline.
Novavax’s breakout would, of course, S.T.E.M. from a pandemic. This is the very thing the company was designed for in the first place.
Consider, in retrospect, this article...
https://journalstar.com/business/investment/markets-and-stocks/is-novavax-inc-a-buy/article_3bda0612-fa59-5618-bb5d-025c127b1772.html" rel="nofollow" target="_blank" >insert-text-here
Now, given the efficacy of NanoFlu (eat it haters), we’re now in the throes of a global pandemic and Novavax has already successfully addressed TWO previous coronaviruses.
Novavax IS the next global leader in vaccination technology.
Lung Delivery Options
1) Nebulizer...inhaled as a diluted solution.
2) Partner with MannKind and utilize the Technosphere technology (dry powder inhalant that goes directly to the lungs’ surfaces.
Either way, it would get where it needs to be to do the most good.
This paragraph is key...
In a broader context, demonstration of Brilacidin’s direct antiviral activity against the SARS-CoV-2 virus supports the drug’s unique 3-in-1 therapeutic potential—antiviral, anti-inflammatory, antimicrobial—to treat COVID-19 and its associated complications. Additional data, based on successfully completed Phase 2 clinical studies in other clinical indications, using various modes of administration, show Brilacidin’s ability to inhibit interleukin-6 (IL-6) and other pro-inflammatory cytokines and chemokines, identified as central drivers in the worsening prognoses of COVID-19 patients. Brilacidin’s robust antimicrobial properties might also help fight secondary bacterial infections, which can co-present in patients with COVID-19.
Manufacturing Agreement now in place
https://www.globenewswire.com/news-release/2020/03/31/2009581/0/en/Emergent-BioSolutions-Signs-Agreement-with-Novavax-to-Manufacture-NanoFlu.html" rel="nofollow" target="_blank" >insert-text-here
Trial also achieves statistical significance in key secondary endpoints
Novavax to submit a U.S. BLA under FDA’s accelerated approval pathway
Company to host investor conference call today at 8:30 a.m. EDT
Webcast Conference Call
Novavax will host a webcast/conference call today at 8:30 a.m. ET. The webcast can be accessed via a link on the home page of the Novavax website (novavax.com) or through the “Investor Info”/“Events” tab on the Novavax website. Listeners who wish to ask questions or don’t have internet access can dial-in to the conference call at (877) 212-6076 (domestic) or (707) 287-9331 (international) and use passcode 4498251.
A replay of the webcast will be available on the Novavax website until June 24, 2020 and a replay of the conference call only will be available starting at 11:30 a.m. ET on March 24, 2020 until 11:30 a.m. ET on March 31, 2020. To access the conference call replay, dial (855) 859-2056 (domestic) or (404) 537-3406 (international) and use passcode 4498251.
Fresh publication in Vaccine journal
https://www.mdpi.com/2076-393X/8/1/99